Trials / Completed
CompletedNCT04634253
A Study of LY3462817 in Participants With Rheumatoid Arthritis
A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug LY3462817 is safe and effective in participants with moderately to severely active rheumatoid arthritis (RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Given IV |
| DRUG | LY3462817 | Given IV |
Timeline
- Start date
- 2021-01-04
- Primary completion
- 2022-01-10
- Completion
- 2022-06-29
- First posted
- 2020-11-18
- Last updated
- 2023-07-12
- Results posted
- 2023-02-01
Locations
26 sites across 7 countries: United States, Czechia, Hungary, Mexico, Poland, Puerto Rico, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04634253. Inclusion in this directory is not an endorsement.